Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q35011129

about

The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases Abiraterone in prostate cancer: a new angle to an old problem CYP17 inhibitors for prostate cancer therapy Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole Dutasteride for the treatment of prostate-related conditions.Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.New hormonal therapies for castration-resistant prostate cancer.Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.Emerging novel therapies in the treatment of castrate-resistant prostate cancer.Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.Targeting 5α-reductase for prostate cancer prevention and treatment Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.New developments in castrate-resistant prostate cancer.The unfolding treatment landscape for men with castration-resistant prostate cancer.Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial.Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer.A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer Androgen synthesis in prostate cancer: do all roads lead to Rome?A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.Castration-resistant prostate cancer: targeted therapies and individualized treatment A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer Q57134465 Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer Cells

P2860

Q21285041-74A531B0-5197-4235-9AD7-9DB59CBE611B Q26828810-5C21AA7A-1EA2-4FD3-998A-01EF2A4CE0FE Q28298818-C7C74C42-0430-4544-A622-CCC69CAC3BA9 Q30537242-2C270E7F-8FCE-4B2A-945B-86B913B244DA Q34252953-50D5CA0C-3D1C-47D0-8DFF-D69394E361EC Q34428508-DDB340C0-B107-4D48-B958-32EF929D6D98 Q34619574-9C660E7C-F687-4745-908C-4F0F7196C561 Q35196715-DCA01DAB-6ECF-46CF-A15D-79314067B0A2 Q35532230-A9C38EB4-C384-450A-8887-A796480E8702 Q35786826-66116247-759C-4D38-A0B0-1322DE51BDE7 Q36241242-26B5DFDE-EBC4-4A91-A90C-9695F0DB6FF5 Q36294923-A8051C5A-59B3-4D64-A65A-5176E9E800C4 Q36416408-EFD36265-7078-4973-AA52-A9E76C11F6A6 Q36483161-FC985580-AE5D-4F8F-9DA0-28E76E488F74 Q36961208-8EAD33EC-7E7C-4B4B-844B-2DED30AC391C Q37762808-7A76423C-ABA2-4A7A-BB1E-FDEB698F9D39 Q37862392-D63CD939-2070-4E2C-AED9-B6BC2F920C60 Q37868056-C04067E6-D43C-4B71-B09B-F7CCEA5C1E79 Q37883012-53D84D76-229E-4D9C-B8ED-730583739EA5 Q37895401-AFC674A4-B438-4212-AD2E-EA5BF06559BC Q38016532-42BD7D64-52F2-4F0E-B4DA-64C463740A99 Q38056914-30E4841A-4A41-49D9-B162-F5740199728E Q38131735-C4DD044C-9C35-4BE0-98F1-4FD49947B562 Q38190112-DDF6BC8C-B198-4934-BB8E-0C145F06CDCB Q38298274-6A8C8A45-2C5D-4DE8-90DE-4D5516604A5C Q38336985-39B73C67-7B8A-4464-9903-6856ADDCE5E6 Q38723579-01C3F16D-105D-4C77-A3C1-7F220E882742 Q39002780-12B09A54-7826-484D-A726-3FD1916CF0C7 Q39144862-38BDE977-32F1-4965-9C74-B73F7F57EEE6 Q39380290-6D65DB8E-4EE1-431E-A550-0F257D23E36E Q39511732-B9A0A5BF-D0AC-4DCB-8BCF-3C7DC399486F Q42174990-EB1D6442-CA02-4657-8B2C-3407B42D47EA Q42188589-8E03442D-D860-471C-95C8-1739B542EDE0 Q57134465-42429F1F-AECC-45F9-97ED-242C2100B721 Q57575109-219199C2-97FB-400B-AB01-ADD6A0F48765 Q58789186-0659BC6D-9866-4A20-A3E5-EE973378B84C

P2860

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q35011129

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II study of androgen syn ...... ion-resistant prostate cancer.

@ast

Phase II study of androgen syn ...... ion-resistant prostate cancer.

@en

type

label

Phase II study of androgen syn ...... ion-resistant prostate cancer.

@ast

Phase II study of androgen syn ...... ion-resistant prostate cancer.

@en

prefLabel

Phase II study of androgen syn ...... ion-resistant prostate cancer.

@ast

Phase II study of androgen syn ...... ion-resistant prostate cancer.

@en

P1433

Q35011129-23160B41-40EF-4285-A9AD-09DDDE0C4B50

P1476

Q35011129-9C528CB9-B4D6-4D8B-BE0A-FAD556205D80

P2093

Q35011129-05AC1E1F-50EE-47BE-83D7-6D5D7C25C3FD

Q35011129-0E9CB1AE-912B-4EAB-AEAB-225F102A8281

Q35011129-2BE7BC35-FB74-44BE-B117-44B1C23696EB

Q35011129-2F681289-FAA3-4DD7-B0A5-6812249B746E

Q35011129-300199EF-6D85-4706-9B04-11121B0DE344

Q35011129-3D120F35-A32E-4C00-B151-75553A967E0C

Q35011129-49722668-3970-4944-9B28-23AFFABA97EE

Q35011129-516DC335-D823-48D8-A3D0-6A81FFAE661C

Q35011129-53715B8B-8FD5-42ED-94F5-B9783D2B9168

Q35011129-7E9FF533-6D41-43B7-AC6B-6B496C60A97E

P2860

Q35011129-13326605-5584-4B4B-A046-AC9517E2DE75

Q35011129-1788BE9B-E24E-4598-A019-F429F4B0609C

Q35011129-1F8A4552-05B8-4BDE-98B9-81998A52D09F

Q35011129-2FC39BA0-73DB-4366-828E-78DB1155BC36

Q35011129-3846F41E-5B8A-4D5B-8FC4-EF107175C9D3

Q35011129-4046A061-30AD-44EF-8288-20C9D4B14F20

Q35011129-491392E5-9352-4261-ABD8-C6839BA929D7

Q35011129-582E8042-F5C2-465D-8862-79F88B449311

Q35011129-5AD9BE3B-E5CA-4A2A-8FD4-BAD49830479D

Q35011129-6BB0BCD4-3BBC-41C8-80B1-D2CC85026B51

P304

Q35011129-D9BF76AE-DE49-4A21-B8CD-2ADF0FEAEAC1

P31

Q35011129-68BC27EF-E7C3-4051-BB87-FDF81932AEF0

P356

Q35011129-74E60B4E-9090-4D78-8F96-E3FDD834D2B0

P407

Q35011129-6B4C586C-18A5-4209-B152-AD804117925A

P433

Q35011129-F5A0B2AD-9EAB-45E0-9A7B-9753B1341CB2

P478

Q35011129-C977DF3D-2053-4B7A-9C6A-F4454907FAF1

P50

Q35011129-480714DD-8665-4DEF-8998-96A7BC766266

Q35011129-BF65ED6F-D9AA-44E7-9A97-D03A343C9752

P577

Q35011129-DA5DE8B6-EDAA-4CF8-B719-FDC2DB6CE835

P698

Q35011129-85F589C2-344C-4E6E-A0B4-263B078CC761

P932

Q35011129-CB02AE25-6F5D-42F6-8AB1-F1960692A991

P356

1078-0432.CCR-09-1722

P1433

Clinical Cancer Research

P1476

Phase II study of androgen syn ...... ion-resistant prostate cancer.

@en

P2093

Christopher W Ryan

http://www.w3.org/2001/XMLSchema#string

Christos S Mantzoros

http://www.w3.org/2001/XMLSchema#string

Glenn J Bubley

http://www.w3.org/2001/XMLSchema#string

Lillian Werner

http://www.w3.org/2001/XMLSchema#string

Meredith M Regan

http://www.w3.org/2001/XMLSchema#string

Oliver Sartor

http://www.w3.org/2001/XMLSchema#string

Paul Mathew

http://www.w3.org/2001/XMLSchema#string

Roger Rittmaster

http://www.w3.org/2001/XMLSchema#string

Samuel R Denmeade

http://www.w3.org/2001/XMLSchema#string

Shi-Ming Tu

http://www.w3.org/2001/XMLSchema#string

P2860

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

Ras signaling in prostate cancer progression.

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

In vivo amplification of the androgen receptor gene and progression of human prostate cancer.

The influence of finasteride on the development of prostate cancer.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.

Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

P304

7099-7105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-1722

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

Mary-Ellen Taplin

P577

2009-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19887483

http://www.w3.org/2001/XMLSchema#string

P932

3644858

http://www.w3.org/2001/XMLSchema#string